Will Daman, Thiqa, and GIG Gulf cover this?

Each insurer assesses named-patient imports case by case. Some reimburse fully when Rezurock is on their formulary even if not currently stocked, some reimburse a percentage subject to copay, and many require pre-authorisation. We supply the documentation set that allows your insurer to assess the case; the claim itself sits with you or your hospital.

Is the FDA-approved indication recognised by EDE?

The EDE named-patient pathway exists precisely to permit access when the local registration or stocking lags the FDA label. The application documents the FDA indication, the reference-authority approval, and the local gap; EDE review focuses on the clinical justification rather than re-litigating the FDA decision.

My physician is licensed in one emirate / state / province and the hospital is in another. Is that fine?

Any UAE-licensed physician practicing in good standing in the jurisdiction of the dispensing facility has signing authority on the clinical justification letter. MOHAP, DHA, DOH, or Sharjah Health Authority verifies the active license; the EDE application records both the prescribing physician and the dispensing facility.

Can I receive Rezurock at home?

The dispensing facility must be UAE-licensed. The hospital outpatient or specialty pharmacy releases the medicine to you after final verification, and you then administer or self-administer at home where the FDA label permits, after the dispensing pharmacy's training. The cold-chain or controlled-storage handoff ends at the dispensing pharmacy; home storage and any handling protocol are part of your patient onboarding kit.

What about competitors or alternative therapies in the same class?

Choice of therapy depends on the patient's full phenotype, prior therapy, and the prescriber's judgment. Reserve Meds coordinates whichever medicine the physician has prescribed; we do not substitute, advise on substitution, or promote one brand over another.

Indicative drug-only band: USD 18,000 to 23,000 per month. Delivered quote within 24h.Get my quote

Rezurock access in the UAE: the EDE named-patient pathway

How patients in the United Arab Emirates legally obtain Rezurock (belumosudil) when the locally registered indication, stocked presentation, or payer coverage does not match what the prescribing physician has written.

Last reviewed 2026-05-12 by Reserve Meds clinical and regulatory team.

Quick orientation

Patients in the UAE access Rezurock (belumosudil) for chronic graft-versus-host disease (cGVHD) in adult and pediatric patients aged 12 years and older after failure of at least two prior lines of systemic therapy through the EDE named-patient pathway, an Emirates Drug Establishment-administered mechanism that allows a UAE-licensed physician at a registered facility to import the FDA-labelled product for a specific named patient. This page details the documentation, approval timeline, and real cost in AED.

Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.

Reserved for you.

How Rezurock reaches patients in the UAE

Rezurock (belumosudil, an oral selective ROCK2 inhibitor, FDA-approved July 2021 for chronic graft-versus-host disease in adult and paediatric patients 12 years and older after failure of at least two prior lines of systemic therapy; marketed by Sanofi after the Kadmon acquisition) is not currently registered with MOHAP or EDE and is not visible on the MOHAP services portal at mohap.gov.ae/en/services as of 2026-05-31. UAE residents access Rezurock through the EDE Permit to Import Medicines for Personal Use, the service transferred from MOHAP to EDE on 29 December 2025 per mohap.gov.ae/en/mte. Hospital-led institutional imports run through the same EDE framework with the treating BMT institution as importer-of-record. The legal basis is Federal Law No. 8 of 2019. The Rezurock-specific clinical justification must document: cGVHD diagnosis (organ-specific NIH consensus criteria), age 12 years or older, history of allogeneic stem cell transplant, failure of at least two prior systemic therapy lines per the FDA label (typically corticosteroids and at least one additional agent: ruxolitinib, ibrutinib, ECP, calcineurin inhibitors), the intended dose of 200 mg once daily orally, and the prescribing BMT team's UAE-licensure. CYP3A4-interaction monitoring (Rezurock dose adjustments with strong inducers or PPI co-administration) is documented in the medical report.

Where Rezurock is dispensed in the UAE

Rezurock is an oral chronic therapy administered in the post-allogeneic-BMT outpatient setting; the dispensing centres are BMT-experienced haematology services. UAE tertiary BMT and haematology nodes include Cleveland Clinic Abu Dhabi (CCAD) BMT and Cellular Therapies in Abu Dhabi at clevelandclinicabudhabi.ae/cancercenter, the country's most active adult BMT and cellular-therapy programme; Sheikh Shakhbout Medical City (SSMC, Mayo Clinic joint venture) Haematology and BMT in Abu Dhabi; Tawam Hospital (SEHA, affiliated with Johns Hopkins) Haematology and Paediatric BMT in Al Ain at seha.ae; Al Jalila Children's Specialty Hospital Paediatric Haematology and BMT in Dubai at aljalilachildrens.ae (for paediatric Rezurock candidates aged 12 and older with paediatric BMT history); American Hospital Dubai Haematology; and Mediclinic City Hospital Haematology in Dubai. CCAD and SSMC carry the largest adult cGVHD case load post-allogeneic-BMT nationally; both publish departmental chairs and run structured GVHD clinics with NIH-consensus organ-specific scoring. Tawam handles paediatric BMT recipients transitioning into adult cGVHD care.

What Rezurock costs in the UAE

The US reference WAC for Rezurock is approximately USD 20,000 to USD 22,000 per 30-day supply at the labelled dose of 200 mg once daily per Sanofi disclosures and Drugs@FDA at accessdata.fda.gov/scripts/cder/daf. Annual WAC at maintenance runs USD 240,000 to USD 260,000. No public AED benchmark for Rezurock is observed on MOHAP or EDE drug-pricing services as of 2026-05-31; the drug is not currently UAE-registered. Do not estimate. Price snapshot: 2026-05-31. The AED is USD-pegged at 3.6725 AED per USD. Cost layers: ambient-temperature international logistics into the UAE (low to mid four-figure USD; Rezurock is a stable oral tablet), EDE personal-import permit fees (nominal), the dispensing BMT-haematology consultation and surveillance schedule (NIH-consensus organ-specific cGVHD scoring, CBC, liver function, CYP3A4-interaction screen), and Reserve Meds concierge fee itemised separately. For Emirati nationals at SEHA-network BMT facilities, the Special-Access institutional procurement route under Thiqa coverage materially reduces OOP exposure.

Funding and access barriers for Rezurock in the UAE

cGVHD affects approximately 30 to 60% of allogeneic stem-cell transplant recipients with corticosteroid-refractory or dependent disease in a meaningful subset. The UAE BMT case load at CCAD and SSMC, plus paediatric BMT at Tawam and Al Jalila, defines the eligible Rezurock population. Public-sector funding: for Emirati nationals, Thiqa-administered Daman insurance at daman.ae covers post-BMT care at SEHA facilities including named-patient imports of cGVHD-specific drugs with prior authorisation; Dubai-resident Emirati nationals on Salama or ENAYA receive comparable cover. MOHAP-administered free care for Emirati nationals applies in the Northern Emirates. For expatriates on mandatory health insurance, major insurers (Daman, Bupa Arabia, AXA Gulf, MetLife, Sukoon, Cigna Middle East, Allianz Worldwide Care, Mednet TPA, Nextcare TPA, NAS TPA) require prior authorisation with documented failure of corticosteroids plus at least one additional systemic therapy line (ruxolitinib, ibrutinib, ECP, calcineurin inhibitors). Sanofi UAE compassionate-access for selected cGVHD patients operates case-by-case. The Patient Affairs Department of HH Sheikh Mohamed bin Zayed (Abu Dhabi) and Mohammed bin Rashid Foundation (Dubai) grants are case-by-case for high-cost rare-disease treatment. The import-permit experience is operationally straightforward for the oral tablet.

Recent regulatory and access news for Rezurock

EMA (CHMP) issued a positive opinion for belumosudil in 2024 with subsequent European Commission marketing authorisation; the EPAR is at ema.europa.eu/medicines/Rezurock. Sanofi continues post-marketing surveillance and is pursuing additional cGVHD-organ-specific data. The FDA Rezurock label is at accessdata.fda.gov/scripts/cder/daf. MOHAP transferred personal-use import permit service to EDE on 29 December 2025 per mohap.gov.ae/en/mte; UAE Rezurock personal-import applications now route through ede.gov.ae. No UAE-specific bulletin on Rezurock over the last 12 months as of 2026-05-31.

Where Reserve Meds fits in Rezurock cases

Reserve Meds is a US-based concierge coordinator. We do not replace your treating physician, we do not replace EDE, and we do not replace your dispensing pharmacy. For Rezurock specifically, we orchestrate the US-side sourcing through a DSCSA-compliant specialty channel, build the documentation packet your physician submits, coordinate validated logistics (cold-chain with continuous temperature logging where the FDA label requires it) into the UAE, and assign a single named coordinator through the case. Standard named-patient coordination under our specialty playbook applies. Presentation selection, dose-band confirmation, and patient onboarding for self-administration where applicable are the recurring operational fundamentals we expect for this drug.

Operationally, a typical Rezurock case runs across four parallel tracks. The clinical track is the physician's: justification letter, dosing plan, monitoring schedule, and the next patient-facing follow-up. The regulatory track is the EDE application packaged by the importer; we provide the documentation template, the dispensing facility license check, and the chain-of-custody attestation. The logistics track is the US-side sourcing and the validated international shipment with continuous temperature logging and customs broker coordination. The patient-experience track is the named coordinator who keeps everyone aligned on dates, addresses dispensing-pharmacy questions, and confirms the medicine has been received and stored correctly. The four tracks are run in parallel rather than in series; that is the operational difference between a 3-week and a 9-week case.

Rezurock is an oral ROCK2 inhibitor for chronic GVHD after two prior lines of systemic therapy; named-patient files document the cGVHD organ involvement (NIH consensus criteria), prior lines including a corticosteroid and a second-line agent, and the baseline liver function (transaminase elevation is on the warnings). The UAE cell-therapy and transplant centres manage these cases.

Next step

If your UAE physician has prescribed Rezurock and you are weighing the cross-border route, the next step is a short intake. We confirm eligibility within 24 to 48 hours and send a documentation kit to your physician.

Start your Rezurock case Or message us on WhatsApp